| Entries |
| Document | Title | Date |
|---|
| 20080199451 | Composition for the Treatment and/or Prevention of Attacks by Biological Agents - A composition for the treatment and/or prevention of attacks by biological agents characterised in that it comprises at least:
| 08-21-2008 |
| 20080206223 | Treatment of pompe's disease - The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than | 08-28-2008 |
| 20080213242 | COMPOSITION AND METHOD FOR TREATING PAPILLOMA VIRUS AND EQUINE SARCOIDS - A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR §1.72(b). | 09-04-2008 |
| 20080233101 | RNA-mediated epigenetic regulation of gene transcription - The invention provides a method of regulating transcription of a gene that is a target for an epigenetic regulator; a method of characterizing the transcriptional activity of such a gene; a method of screening for a chromosomal element (CE) for an epigenetic regulator of a target gene; an isolated complex including an epigenetic regulator for a target gene, wherein the epigenetic regulator is specifically bound to a non-coding polynucleotide; and a method of screening for a modulator of transcription of a gene that is a target for an epigenetic regulator. | 09-25-2008 |
| 20080248019 | Recombinant beta-galactosidase derived from Streptococcus pneumaniae - The present invention relates to a novel beta-galactosidase derived from | 10-09-2008 |
| 20080248020 | Heparanases and Splice Variants Thereof, Ponucleotides Encoding Them and Uses Thereof - The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to | 10-09-2008 |
| 20080260716 | Method and Composition for High Level Disinfection Employing Quaternary Ammonium Compounds - Methods and compositions for high level disinfection (as herein defined) of a surface. Methods include treating the surface with a composition including a quaternary ammonium compound in a concentration which exceeds 1% w/w and the temperature of treatment is in the range of from 30° C. to 80° C. A log (6) reduction in | 10-23-2008 |
| 20080286257 | Compounds for Use in Treating Abnormal Cell Proliferation, and Methods of Producing Same - The invention relates to the modification of recombinant human lysozyme from genetic engineering (rHLys) by reacting with activated polyethylene glycols (PEGs), which are partially binding or saturating with typical linkers one or more out of the six free amino groups of the five lysines (K) present in the rHLys chain. The resulting conjugate compounds of the invention (PEG-rHLys) and their addition salts, inhibit the abnormal cell proliferation and show remarkable antiproliferative and antimetastatic effects. The invention relates also to the use of the new compounds in the preparation of pharmaceutical compositions for treating a disease associated with abnormal cell proliferation, including cancer, by administering said conjugates to a subject in need thereof. | 11-20-2008 |
| 20090010914 | Use of Oligouronates for Treating Mucus Hyperviscosity - The invention provides a method of treatment of a human or non-human subject to combat mucosal hyperviscosity in the respiratory tract, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate. | 01-08-2009 |
| 20090010915 | Methods for Conducting Metabolic Analyses - The present invention provides methods and apparatus for purifying metabolites of interest and conducting metabolic analyses. The methods generally involve determining metabolic flux values for a plurality of target analytes by monitoring the relative isotope abundance of a stable isotope in a substrate labeled with the stable isotope and/or one or more target metabolites formed through metabolism of the labeled substrate. Certain methods utilize multiple electrophoretic methods to separate the target analytes from other components within the sample being analyzed. The methods can be used in a variety of applications including screens to identify metabolites that are correlated with certain diseases and diagnostic screens for identifying individuals having, or susceptible to, a disease. | 01-08-2009 |
| 20090017005 | Delivery of Therapeutic Compounds to the Brain and Other Tissues - The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human α-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan (GAG) storage in cells of MPS I subjects to that of normal subjects. Intrathecal administration proved more effective than intravenous treatment at alleviating MPS I symptoms, indicating it is a useful method of treating lysosomal storage disorders. | 01-15-2009 |
| 20090035293 | Amylases for Pharmaceutical Use - The pharmaceutical use of amylases related to | 02-05-2009 |
| 20090047272 | Compositions with Modified Nucleases Targeted to Viral Nucleic Acids and Methods of Use for Prevention and Treatment of Viral Diseases - Antiviral compositions comprising a modified nuclease, or a plurality of such modified nucleases having at least one non-natural amino acid residue substituted for a naturally occurring amino acid in a parent nuclease are provided, as are methods of use and kits providing unit dosages of such compositions. | 02-19-2009 |
| 20090068167 | COMPOSITIONS FOR PROMOTING WOUND HEALING AND TREATING PSORIASIS - The present invention relates to compositions and methods for promoting healing of cutaneous, mucosal and/or mucocutaneous lesions associated with the presence of a mycoplasma and one or more non-mycoplasma microorganisms. The compositions and methods of the invention also relate to the reduction of joint pain, column pain, and/or skeletal muscle pain | 03-12-2009 |
| 20090081184 | NON-PANCREATIC PROTEASES FOR CONTROLLING PLASMA CHOLECYSTOKININ (CCK) CONCENTRATION AND FOR TREATING PAIN - This invention relates to methods for maintaining the basal level or reducing the level of cholecystokinin (CCK) in blood plasma of a mammal. Additionally, the invention provides methods for treating pain in a mammal and more particularly, methods for treating abdominal pain in a mammal. The methods include administering to the mammal a non-pancreatic protease or a composition comprising a non-pancreatic protease. The methods of this invention are particularly useful for treating abdominal pain in a mammal suffering from acute or chronic pancreatitis and related conditions. | 03-26-2009 |
| 20090104173 | NOVEL PROCESS FOR SOLUBILIZING PROTEIN FROM A PROTEINACEOUS MATERIAL AND COMPOSITIONS THEREOF - The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention. | 04-23-2009 |
| 20090117091 | Methods for treating pompe disease - The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor in a mannose-6-phosphate-independent manner. | 05-07-2009 |
| 20090123451 | SLOW INTRAVENTRICULAR DELIVERY - Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier. Similarly, diagnostic agents and anesthetic agents can be delivered to the brain in this manner. The administration can be performed slowly to achieve maximum effect. Such administration permits greater penetration of distal portions of the brain. | 05-14-2009 |
| 20090130081 | Method for treating pervasive development disorders - A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. | 05-21-2009 |
| 20090130082 | Compositions and methods for the treatment and prevention of infections caused by staphylococcus aureus bacteria - The present invention relates to antimicrobial deoxyribonuclease-based compositions that inhibit growth and proliferation of | 05-21-2009 |
| 20090142326 | Glycosidase Enzymes - A thermostable glycosidase enzymes derived from various | 06-04-2009 |
| 20090142327 | Novel Class of Therapeutic Protein Based Molecules - The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy. | 06-04-2009 |
| 20090148432 | COMPOSITIONS FOR INHIBITING ATHEROSCLEROSIS - The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol. | 06-11-2009 |
| 20090148433 | METALLO-PROTEIN AND TOCOTRIENOL (MP-T3) COMPOSITIONS AND USES THEREOF - Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements. | 06-11-2009 |
| 20090155238 | XYLANASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal β-1,4-xylosidic linkages or endo-β-1,4-ghicanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature. | 06-18-2009 |
| 20090162340 | STABLE GALENIC FREEZE-DRIED PHARMACEUTICAL PREPARATION OF RECOMBINANT CARBOHYDRATE-BINDING POLYPEPTIDES - The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused with cytotoxically effective peptides to give fusion proteins, or which are linked to another polypeptide having a cytotoxic activity. Moreover, the invention describes further formulating of the disclosed medicaments to medicaments with different pharmaceutical forms. | 06-25-2009 |
| 20090191178 | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof - This invention provides compositions of highly phosphorylated lysosomal enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases. | 07-30-2009 |
| 20090202514 | AGENTS FOR IMPROVING CHRONIC OBSTRUCTIVE PULMONARY DISEASES - The present invention relates to agents for suppressing pulmonary emphysematous lesions and agents for suppressing emphysematous lesions which are suitable for treating and/or preventing COPD, which comprise as an active ingredient a substance having an activity of promoting CSPG degradation, inhibiting CSPG synthesis, or inhibiting CSPG sulfation (examples of such agents are: chondroitinase ABC, C6ST antisense agents, and GalNAc antisense agents); agents for treating and/or preventing COPD; methods for suppressing emphysematous lesions; and methods for treating and/or preventing COPD. | 08-13-2009 |
| 20090202515 | AGENTS FOR SUPPRESSING NEURAL FIBROTIC DEGENERATION - The present invention examined the accumulation of chondroitin sulfate proteoglycans (CSPGs). The present invention relates to neurodegeneration-suppressing agents that are suitable for gene therapy or prevention of neural fibrotic degenerative diseases which induce neural cell death due to an accumulation of abnormal proteins, where the therapies are based on siRNAs against N-acetylgalactosamine-4-O-sulfotransferases (N-acetylgalactosamine-4-O-sulfotransferase-1, N-acetylgalactosamine-4-O-sulfotransferase-2, and N-acetylgalactosamine-4-sulfate 6-O-sulfotransferase (GalNAc4ST-1, GalNAc4ST-2, and GALNAC4S-6ST, respectively)), which are sulfotransferases for acetylgalactosamine, a CSPG side chain, and chondroitinase ABC, an enzyme that degrades chondroitin sulfate, another CSPG side chain. | 08-13-2009 |
| 20090202516 | INHIBITION AND TREATMENT OF GASTROINTESTINAL BIOFILMS - Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of gastrointestinal biofilm infections, and associated systemic symptoms caused by biofilms associated microorganisms within the gastrointestinal tract. Methods of identification, preparation and use of such physiologically acceptable anti-biofilm compositions are also provided. | 08-13-2009 |
| 20090214511 | DIGESTIBLE COMPOSITIONS OF INULIN FOR MANAGING BLOOD GLUCOSE LEVELS - Digestible compositions of inulin for managing blood glucose levels in a patient are disclosed. The compositions can include an inulin, a sucrose and an amylase, wherein the inulin is configured to lower blood glucose in the patient and wherein the sucrose is presented in sufficient amount to at least partially counteract the blood glucose lowering effect of the inulin. Several embodiments disclosed in the present application include a vegetable mixture comprising burdock root, carrots and daikon radish and additional constituents such as dimethyl sulfoxide, lentinan and D-eritadenine. Additionally, methods of preparing a digestible composition of inulin are also disclosed. | 08-27-2009 |
| 20090220480 | CELLULOLYTIC ENZYMES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention provides polypeptides having any cellulolytic activity, e.g., a cellulase activity, a endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a β-xylosidase, an arabinofuranosidase, and/or an oligomerase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, β-xylosidase, arabinofuranosidase, and/or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. In one aspect, the invention provides polypeptides having an oligomerase activity, e.g., enzymes that convert recalcitrant soluble oligomers to fermentable sugars in the saccharification of biomass. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts. The invention also provides compositions or products of manufacture comprising mixtures of enzymes comprising at least one enzyme of this invention. | 09-03-2009 |
| 20090220481 | METHOD AND COMPOSITIONS FOR TREATING SKIN - A skin care composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; a method for inhibiting damage to human keratinocytes due to environmental aggressors by applying a composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; and a method for repairing DNA damage in human keratinocytes. | 09-03-2009 |
| 20090252719 | USE OF FRUCTANASES IN FEED OF HOOFED ANIMALS, PREFERABLY TO PREVENT DISEASES - Laminitis is defined as an inflammation of the sensitive laminae of the hoof, especially in horses. It has been surprisingly found that fructanases such as 2,1-β-D-fructan hydrolase are highly effective as therapeutic and prophylactic agents against laminitis in horses. The fructanases may be used as enzyme compositions in horse feed, as additives for horse feed or as oral preparations for the therapy and prophylaxis of laminitis. Because of its effectiveness in hydrolyzing fructans, which seem to play an important role in the aetiology of laminitis, the administration of fructanases in combination with an increased intake of fructans or with an increased availability of fructans is particularly advantageous. | 10-08-2009 |
| 20090258000 | MUCOSALLY NON-IRRITATIVE AMPHOTERICIN B FORMULATIONS AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS - The present invention is directed to compositions and methods for non-irritatively treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves compositions including a mucosally non-irritative mixture of amphotericin B and a pharmaceutically acceptable carrier. Such compositions can be non-irritatively mucoadministered to prevent, reduce, or eliminate chronic non-invasive fungus-induced mucositis conditions. | 10-15-2009 |
| 20090263371 | Use Polysaccharides for Promotion of Enzymatic Activity - This disclosure provides methods and compositions for the promotion of enzymatic activity of Target Enzymes, including but not limited to oligosaccharide/polysaccharide enzymes, protein enzymes, polynucleotide enzymes. The methods involve use of a non-naturally occurring polysaccharide (including but not limited HES) for promoting the enzymatic activity of an enzyme in liquid milieu, wherein the concentration of the polysaccharide in the composition comprising the Target Enzyme is from about 0.01% to about 55% w/v. | 10-22-2009 |
| 20090263372 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF THE SYMPTOMS OF ADDICTION AND METHOD OF DIAGNOSING SAME - A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed. | 10-22-2009 |
| 20090274682 | DEMETHYLATION AND INACTIVATION OF PROTEIN PHOSPHATASE 2A - Embodiments of the present invention relate to atomic coordinates for PME-1 alone or in complex with PP2A, as well as methods for using these atomic coordinates to prepare inhibitors of PME-1 and/or PP2A and inhibitors prepared using such methods. Further embodiments relate to biochemical analyses of the interactions of PME-1 alone or in complex with PP2A. Further embodiments relate to compositions including mimetics and small molecules, optionally, secondary agents, which may be used to treat disorders in which PME-1 and/or PP2A activity plays a contributing role. | 11-05-2009 |
| 20090280105 | Novel Fungal Enzymes - This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method to convert lignocellulosic biomass to fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. The invention also relates to methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, deinking and biobleaching of paper and pulp, and treatment of waste streams. | 11-12-2009 |
| 20090297497 | Methods and compositions for treating nephrogenic diabetes and insipidus - Disclosed are compositions and methods for treating nephrogenic diabetes insipidus and for induction of diuretic effect. | 12-03-2009 |
| 20090304668 | LARVAL POLYPEPTIDES HAVING A NUCLEASE ACTIVITY - This invention relates to a polypeptide obtainable from insect larvae, such as those from | 12-10-2009 |
| 20090311236 | Therapeutic Peptide Compositions And Methods Of Making And Using Same - Therapeutic compositions include peptide formulations having a mixture of serum, albumin, casein, peptone, pacreatin, and sodium hydroxide. The peptide compositions do not include nucleic acid or any derivatives thereof. The peptide compositions have beneficial therapeutic properties to boost human immune system and to treat various ailments including malaria, allergy and inflammation. The peptide compositions, one having a molecular weight greater than 10 kDa and having amino acid residues in a range of 27 and 315, and the other having a molecular weight equal to or less than 10 kDa and amino acid residues in a range of 27 and 54, their structures and therapeutic properties are discussed. | 12-17-2009 |
| 20100003234 | Cellulases, Nucleic Acids Encoding Them and Methods for Making and Using Them - This invention relates to molecular and cellular biology and biochemistry. In one aspect, the invention provides polypeptides having cellulase activity, e.g., endoglucanase, cellobiohydrolase, mannanase and/or β-glucosidase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides cellulase activity, e.g., endoglucanase, cellobiohydrolase, mannanase and/or β-glucosidase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts. | 01-07-2010 |
| 20100003235 | ORAL FORMULATIONS FOR ENTERIC DISORDERS AND/OR REHYDRATION - The present invention relates, generally, to oral formulations including one or more recombinantly-produced human milk proteins. The formulations of the present invention may be used to prevent the onset of diarrhea in patients who have been or will be exposed to one or more agents known to cause diarrhea, and to prevent the recurrence of diarrhea in a patient recovering therefrom. The formulations may also be used in the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The formulations may also be beneficially administered in accordance with methods for promoting the development of healthy intestinal flora in a human patient. | 01-07-2010 |
| 20100003236 | USE OF C-GLYCOSIDE DERIVATIVES AS PRO-DESQUAMATING ACTIVE AGENTS - A cosmetic use of at least one C-glycoside derivative in a composition comprising a physiologically acceptable medium, as a cosmetic agent for promoting the desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal. | 01-07-2010 |
| 20100008897 | COMPOSITION FOR PROVIDING A BENEFIT TO A KERATIN-CONTAINING SUBSTRATE - This invention relates to compositions and methods for providing cosmetic and other potential benefits to keratin-containing substrates. The compositions contain at least one naturally-occurring cationic protein with a biological function in a cosmetically acceptable carrier, such that the naturally-occurring cationic protein retains its essential configuration, preserving its biological function, when it is in proximity to a keratin-containing substrate. | 01-14-2010 |
| 20100028322 | ANTIMETASTATIC EFFECT ON HUMAN CELL DISORDERS - Use of recombinant human lysozyme in the preparation of a medicament for controlling life-threatening diseases associated with abnormal cell proliferation and migration, such as cancer metastasis, by administering to a subject in need thereof therapeutically effective doses of recombinant human lysozyme to elicit said antiproliferative and antimetastatic effects. | 02-04-2010 |
| 20100028323 | VERMIN EXTERMINATION USING LYSOZYME, SALT OR BIOLOGICAL FRAGMENT THEREOF, OR LYSOZYME-RELATED PEPTIDE AS AN EGG RECOGNITION PHEROMONE - The present invention provides a mimetic egg comprising lysozyme, a salt or biological fragment thereof or a lysozyme-related peptide and an active ingredient in its base material mimicking an egg of a vermin; and a vermin exterminating method using the mimetic egg. | 02-04-2010 |
| 20100028324 | Creating Designer Antimicrobials; Peptidoglycan Hydrolase Module Shuffling - The invention concerns a nucleic acid encoding a recombinant bifunctional fusion peptidoglycan hydrolase protein formed from a nucleic acid encoding a peptidoglycan hydrolase module and a nucleic acid encoding a second peptidoglycan hydrolase module. The fusion, dual (or multiples thereof) peptidoglycan hydrolase modules can be used to treat disease caused by the bacteria for which the individual modules of the fusion protein are specific. | 02-04-2010 |
| 20100028325 | New Combination Of Cationic Preservatives With Taste-Masking Components - Use of cationic surfactants, derived from the condensation of fatty acids and esterified dibasic amino acids, of the formula (1): | 02-04-2010 |
| 20100034801 | Non-Polymeric Compositions for Controlled Drug Delivery - The present invention provides a novel liquid composition suitable for in-situ formation of a depot system to deliver a bioactive substance in a controlled manner. The composition of the present invention comprises: (a) a hydrophobic non-polymeric carrier material; (b) a water miscible biocompatible organic solvent that dissolves the hydrophobic non-polymeric material; (c) an ionic complex that is formed between an amphiphilic molecule and a bioactive substance having a net charge at neutral pH in water. The present invention also provides a method of manufacturing and use of the composition thereof. | 02-11-2010 |
| 20100040595 | XYLANSES FOR ANIMAL FEED - The present invention relates to the use in animal feed of a xylanase having a percentage of identity to a | 02-18-2010 |
| 20100080790 | STERILIZATION USING HIGH-PRESSURE CARBON DIOXIDE - Disclosed are compositions and methods for the biocompatible sterilization of materials, in particular, of medical devices and implants. Sterilization is achieved by deactivation of microorganisms through treatment of the material with a mixture of at least one microbiocidal additive and a high-pressure or supercritical fluid, for example, high-pressure carbon dioxide or supercritical carbon dioxide. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 04-01-2010 |
| 20100092449 | Treatment of Pompe's Disease - The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. | 04-15-2010 |
| 20100104549 | GLUFOSFAMIDE COMBINATION THERAPY - The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment. | 04-29-2010 |
| 20100119502 | THERAPY REGIMENS, DOSING REGIMENS AND STABLE MEDICAMENTS FOR THE TREATMENT OF POMPE DISEASE - The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in vivo stability of a GAA enzyme formulation. | 05-13-2010 |
| 20100135981 | USE OF THE ENDOGLYCOSIDASE ENDOS FOR TREATING IMMUNOGLOBULIN G MEDIATED DISEASES - The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies. | 06-03-2010 |
| 20100135982 | SIMETHICONE SOLID ORAL DOSAGE FORM - The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. | 06-03-2010 |
| 20100158889 | ENHANCING THE EFFECT OF THERAPEUTIC PROTEINS ON THE CENTRAL NERVOUS SYSTEM - The present invention provides a polypeptide therapeutic agent, useful in enzyme replacement therapy, with increased therapeutic benefits for the central nervous system. The invention provides a method of enhancing the effect of a polypeptide or protein on the central nervous system by the attachment of a short acidic amino acid sequence. Specifically the inventors disclose the attachment of a 4-15 acidic amino acid sequence to human β-glucuronidase by construction of a fusion protein. This molecule is useful in the treatment of type VII mucopolysaccharidosis when administered to a patient. | 06-24-2010 |
| 20100166728 | Novel Highly Functional Enzyme Having Modified Substrate-Specificity - The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 07-01-2010 |
| 20100178285 | SYNERGISTIC ANTHELMINTIC COMPOSITION - The present invention discloses novel synergistic anthelmintic compositions used for prevention and treatment of gastrointestinal nematodes comprising combination of therapeutically effective amount of ginger extract with proteolytic enzyme and fibre degrading enzymes. The novel anthelmintic compositions provide synergistic effect at comparatively lower doses which are affordable and impart minimal/no side effect on general health as well as milk yield of dairy animals. | 07-15-2010 |
| 20100189708 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE - The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease. | 07-29-2010 |
| 20100196345 | PRODUCTION OF HIGH MANNOSE PROTEINS IN PLANT CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 08-05-2010 |
| 20100221235 | Compositions and Methods for Treating Lysosomal Storage Diseases - The invention relates to chimeric polypeptides comprising a lysosomal peptide fused or conjugated to at least one cell-penetrating peptide (CPP). Also provided by the invention are methods for treating a subject suffering from lysosomal storage disorders (LSD). | 09-02-2010 |
| 20100226908 | COMPOSITIONS FOR PROMOTING WOUND HEALING AND TREATING PSORIASIS - The present invention relates to compositions and methods for promoting healing of cutaneous, mucosal and/or mucocutaneous lesions associated with the presence of a mycoplasma and one or more non-mycoplasma microorganisms. The compositions and methods of the invention also relate to the reduction of joint pain, column pain, and/or skeletal muscle pain | 09-09-2010 |
| 20100239559 | Novel nutritional food products for improved digestion and intestinal absorption - The present invention is directed to novel food products, e.g., nutritional food products and infant formula, which contain one ore more enzymes selected from lipase, protease, and amylase that have been formulated/stabilized to have sustained stability in an aqueous medium. Such formulations are intended to provide a greater degree of compliance based on their ability to be incorporated into aqueous media while avoiding unstable breakdown of the enzyme and large overdosing due to expected breakdown when exposed to an aqueous environment, including saliva. Further described in the invention are additives packaged with instructions for combination with an aqueous medium, and instructions for the administration of the resulting mixture to a subject. In certain embodiments, enzyme insufficient patients, e.g., infants and elderly persons, would find particular benefit from the food products described herein. | 09-23-2010 |
| 20100254966 | TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II - Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. | 10-07-2010 |
| 20100254967 | METHODS AND MATERIALS FOR REDUCING BIOFILMS - This document provides methods and materials related to reducing biofilms. For example, enzymes (e.g., glycosyl hydrolases), nucleic acid molecules encoding enzymes, host cells containing nucleic acid encoding enzymes, and methods for using enzymes to reduce biofilms and infections associated with biofilms are provided. | 10-07-2010 |
| 20100260740 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS - The present invention provides methods for preventing and/or treating lysosomal storage disorders using 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease. | 10-14-2010 |
| 20100278805 | COMPOSITIONS FOR INHIBITING ATHEROSCLEROSIS - The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol. | 11-04-2010 |
| 20100284994 | USE OF EDTA AND ITS DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INTESTINAL DISEASES OF PIGS AND FOR INCREASING THE EFFECTS OF ANTIBIOTICS EXERTED IN SUCH DISEASES - The invention relates to the use of ethylenediamine tetraacetic acid (EDTA) and its derivatives, i.e. its salts and complexes for prevention and treatment of bacterial intestinal diseases of pigs and for increasing the effects of antibiotics exerted in such diseases. The invention also relates to compositions for animal husbandry, i.e. to veterinary compositions and to feeds and drinks which can be consumed by pigs, comprising EDTA or its derivatives. | 11-11-2010 |
| 20100291059 | PHARMACEUTICAL COMPOSITION FOR ENZYME REPLACEMENT THERAPY - The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an α-galactosidase activity through alteration of the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 11-18-2010 |
| 20100291060 | SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A - The invention relates, in part, to improved methods of administering α-galactosidase A for the treatment of α-galactosidase A deficiencies including Fabry disease. | 11-18-2010 |
| 20100303797 | Use of p97 As An Enzyme Delivery System For The Delivery of Therapeutic Lysosomal Enzymes - The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier. | 12-02-2010 |
| 20100310545 | Dry treatment mixture and methods of production and use - A dry treatment mixture is provided including: a quantity of a dry formulation of a salt; and a quantity of a dry formulation of lysozyme. The salt preferably is sea salt. The dry treatment mixture preferably additionally includes a dry formulation of lactoferrin. A method of producing a dry treatment mixture preferably includes the steps of: providing a quantity of a dry formulation of salt in one of powder form and granular form; providing a quantity of a dry formulation of lysozyme; and mixing the quantity of a dry formulation of salt and the quantity of a dry formulation of lysozyme together to form a dry treatment mixture. The method optionally includes the yet additional step of compressing a quantity of the mixture in a mold to form a mixture pill or of encapsulating the quantity of the mixture in a capsule for oral administration, or impregnating a bandage with the mixture for topical administration. | 12-09-2010 |
| 20100322915 | Protease Variants for Pharmaceutical Use - The invention relates to novel variants of a protease derived from | 12-23-2010 |
| 20100322916 | DNA REPAIR POLYPEPTIDES AND METHODS OF DELIVERY AND USE - Described herein are pyrimidine dimer-specific glycosylase (PDG) polypeptides and methods of use for repair of damaged DNA. The PDG polypeptides comprise amino acid sequence from T4-PDG, CV-PDG or engineered mutants thereof. The PDG polypeptides further comprise a targeting sequence, such as a nuclear targeting sequence or a mitochondrial targeting sequence, and a protein transduction domain. The mutant PDG polypeptides described herein retain at least some catalytic activity while exhibiting reduced cytotoxicity in wild-type cells. | 12-23-2010 |
| 20100330062 | KLOTHO PROTEIN AND RELATED COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF CANCER - Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents. | 12-30-2010 |
| 20110002908 | TREATMENT OF A-GALACTOSIDASE A DEFICIENCY - The invention provides methods of treating α-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human α-galactosidase A are also included. | 01-06-2011 |
| 20110014178 | Antimicrobial Composition and Method for Use - An antimicrobial composition and a method for administering the antimicrobial composition through the water or feed of livestock, wherein the antimicrobial composition is made up of lysozyme and various other agents that act synergistically with lysozyme, such as, dried egg powder, albumen, a sequestering agent and/or a lantibiotic. The composition is used to inhibit the growth of, and diseases and epidemiological significant effects caused by, | 01-20-2011 |
| 20110027252 | Variants of An Alpha-Amylase with Improved Production Levels in Fermentation Processes - Variants of | 02-03-2011 |
| 20110027253 | PADLOCK PROBE AMPLIFICATION METHODS - The present invention relates to an enzyme activity assay using rolling circle 5 amplification for verifying that a sample contains enzyme activity. The enzyme activity assayed is typically involved in processing of mismatched nucleotides and/or damaged nucleotides in a double stranded nucleic acid. The present invention relates to methods for determining the presence of enzyme activities involved in processing double stranded oligonucleotide. Methods are also directed against determining the presence | 02-03-2011 |
| 20110027254 | COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE - Methods and compositions for treating Gaucher disease are described. | 02-03-2011 |
| 20110027255 | Composition and Method for Treating Papilloma Virus and Equine Sarcoids - A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids. | 02-03-2011 |
| 20110033439 | TARGETED ANTIMICROBIALS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Targeted antimicrobials are described and related, compositions, methods and systems. | 02-10-2011 |
| 20110033440 | NOVEL PROCESS FOR SOLUBILIZING PROTEIN FROM A PROTEINACEOUS MATERIAL AND COMPOSITIONS THEREOF - The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention. | 02-10-2011 |
| 20110044969 | Antimicrobial Agents for the Treatment of Campylobacter Species in the Crop of a Bird - The invention provides an antimicrobial agent for use in the treatment of a | 02-24-2011 |
| 20110064718 | Pesticidal and Antiparasitic Compositions - This invention relates to pesticide and antiparasitic compositions for the control of pests, diseases and parasites attacking plants and animals. The compositions include, at least one chitinolytic agent or a chitinolytic activity-inducing agent, and sulfide or a sulfide-producing agent from microorganisms or chemical compounds, wherein the chitinolytic agent or the chitinolytic activity-inducing agent and sulfur or a sulfur-producing agent obtaining from microorganisms or chemical compounds are concurrently applied at a range significantly lower than any of the above-mentioned compounds, when they are individually to attain effective control. | 03-17-2011 |
| 20110070219 | HIGH PRESSURE PROTEIN CRYSTALLIZATION - The present disclosure provides an effective method for the crystallization of proteins at high pressure. A preferential excluding agent, and optionally other reagents may be incorporated into the method. The method is applicable to substantially all proteins. | 03-24-2011 |
| 20110070220 | Immunomodulating gene therapy - The present invention relates, in general, to Pompe disease and, in particular, to a methods of treating Pompe disease and to compounds/constructs suitable for use in such methods. | 03-24-2011 |
| 20110086016 | Enzymatic pre-mixture against Gram negative bacteria colonization in the animal intestinal tract - The invention provides pre-mixture for animal feeding comprising: (a) a polymer or a mixture of polymers, with a content in mannose comprised between 10% and 100%; (b) β-mannanase enzyme; and (c) an anti-binding agent; wherein the anti-binding agent has an absorptive capacity higher than 20%, and a bulk density which is comprised between 0.10 and 2.70 g/cm | 04-14-2011 |
| 20110091441 | MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM THE HUMAN INTERLEUKIN-2 RECEPTOR GAMMA CHAIN GENE AND USES THEREOF - An I-CreI variant, wherein at least one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the human IL2RG gene. Use of said variant and derived products for the prevention and the treatment of X-linked severe combined immunodeficiency. | 04-21-2011 |
| 20110091442 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS - The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease. | 04-21-2011 |
| 20110104140 | USE OF NON-CATALYTIC FORM OF HEPARANASE AND PEPTIDES THEREOF FOR REVERSING THE ANTI-COAGULANT EFFECTS OF HEPARINOIDS - The present invention relates to inhibition of heparinoids anti-coagulation activity by a non-active form of a eukaryotic endoglycosidase or any fragment or peptide thereof comprising at least one heparin-binding domain. More particularly, the invention provides compositions and methods for the inhibition of heparinoids anti-coagulation activity and for the treatment of coagulation related pathologic clinical conditions, using a non-active form of mammalian heparanase or peptides thereof comprising at least one heparin-binding domain. | 05-05-2011 |
| 20110104141 | Methods for Preventing, Removing, Reducing, or Disrupting Biofilm - The present invention relates to methods for preventing, removing, reducing, or disrupting biofilm present on a surface, comprising contacting the surface with an alpha-amylase derived from a bacterium. | 05-05-2011 |
| 20110110919 | MIXTURE OF PEPTIDE-BOUND TRYPTOPHAN AND POLYPEPTIDE-BOUND TRYPTOPHAN - The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan. | 05-12-2011 |
| 20110135624 | THERAPEUTIC COMPOSITION FOR AUTOIMMUNE CONDITIONS - A therapeutic composition for the treatment, alleviation or prophylaxis of autoimmune conditions is described. The composition comprises an enzyme and an immunogen appropriate to the condition to be treated. The composition may be given in conventional fashion but is preferably given by intradermal injection. | 06-09-2011 |
| 20110142818 | COMBINATION ENZYME REPLACEMENT AND SMALL MOLECULE THERAPY FOR TREATMENT OF LYSOSOMAL STORAGE DISEASES - This invention provides various combinations of enzyme replacement therapy, gene therapy, and small molecule therapy for the treatment of lysosomal storage diseases. | 06-16-2011 |
| 20110171198 | HIGHLY FUNCTIONAL ENZYME HAVING ALPHA-GALACTOSIDASE ACTIVITY - The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 07-14-2011 |
| 20110182875 | NOVEL CLASS OF THERAPEUTIC PROTEIN BASED MOLECULES - The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy. | 07-28-2011 |
| 20110217283 | STABLE GALENIC FREEZE-DRIED PHARMACEUTICAL PREPARATION OF RECOMBINANT CARBOHYDRATE-BINDING POLYPEPTIDES - The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused with cytotoxically effective peptides to give fusion proteins, or which are linked to another polypeptide having a cytotoxic activity. Moreover, the invention describes further formulating of the disclosed medicaments to medicaments with different pharmaceutical forms. | 09-08-2011 |
| 20110223148 | THERAPEUTIC/PROPHYLACTIC AGENT FOR PROSTATE CANCER - Provided are a novel therapeutic agent and therapeutic method for prostatic cancers. More specifically, a prostatic cancer therapeutic/prophylactic agent having a viral envelope vector, particularly a Sendai viral envelope vector, as an active ingredient, the therapeutic/prophylactic agent which is an apoptosis induction promoter, the therapeutic/prophylactic agent used for prostatic cancers whose androgen susceptibility has been partially or completely reduced, and a melanoma therapeutic/prophylactic agent containing a Sendai viral envelope vector as the only active ingredient, and the like are provided. | 09-15-2011 |
| 20110236366 | PRODUCTION AND USES OF TYPE I RIBOSOME INACTIVATING PROTEINS - Described herein are methods to express and purify recombinant type 1 ribosome inactivating proteins. Included are methods for using recombinant cucurmosin as a therapeutic to treat cancer and infectious diseases. | 09-29-2011 |
| 20110268721 | Therapy Regimens, Dosing Regimens And Stable Medicaments For The Treatment Of Pompe Disease - The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in vivo stability of a GAA enzyme formulation. | 11-03-2011 |
| 20110280856 | TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY - The invention provides highly purified α-Gal A, and various methods for purifying it; α-Gal A preparations with altered charge and methods for making those preparations; α-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an α-Gal A preparation to a subject. | 11-17-2011 |
| 20110318327 | TREATMENT OF SANFILIPPO SYNDROME TYPE B - Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety. | 12-29-2011 |
| 20110318328 | Specific Lysis of Staphylococcal Pathogens by Bacteriophage phi11 Endolysin | 12-29-2011 |
| 20120045425 | DELTA 4, 5 GLYCURONIDASE COMPOSITIONS AND METHODS RELATED THERETO - The invention relates to Δ4,5 glycuronidase, related compositions, and methods of use thereof. | 02-23-2012 |
| 20120064058 | COMPOSITIONS FOR PROTEIN-BASED DIETARY PRODUCTS - A human use dietary product composition to reduce fat body mass without substantially reducing lean body mass, in obese or overweight patients includes a protein component and an amino acid additional component, the additional component containing a determined amount of lysine and/or tryptophan such that on the whole lysine and tryptophan in the composition have a weight ratio set between 2.5 and 4. To cope with typical protein-based diets drawbacks, the composition further includes an amino acid additional component with an amino acid selected from the group including lysine and/or tryptophan, in an amount such that on the whole the lysine and tryptophan in the composition have a weight ratio set between 2.5 and 4. The composition further contains a component that may be a polysaccharide or an enzyme, or a combination thereof. The enzyme may be α-Galactosidase, Lactase, an enzyme having a flatulence reducing action, or a combination thereof. | 03-15-2012 |
| 20120076767 | PROCESS FOR CONCENTRATION OF A POLYPEPTIDE - The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection. | 03-29-2012 |
| 20120114627 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISORDERS CHARACTERIZED BY UNDESIRABLE CELL PROLIFERATION - The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol. The present invention also relates to methods for the diagnosis, prevention and treatment of atherosclerosis and mycoplasma associated diseases, cardiotoxicity related to cancer treatment, and Chagas disease related cardiomyopathies. | 05-10-2012 |
| 20120141452 | Targeted Therapeutic Proteins - Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided. | 06-07-2012 |
| 20120141453 | Glycosidase Enzymes - A thermostable glycosidase enzymes derived from various | 06-07-2012 |
| 20120189607 | METHOD OF REGULATING FERTILIZING ABILITY USING CYCLIC ADP-RIBOSE AND CD38 - The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD | 07-26-2012 |
| 20120189608 | NEW ENDOLYSIN OBPGPLYS - The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide or fusion protein. | 07-26-2012 |
| 20120195876 | NOVEL ROLE OF ALPHA-GALACTOSIDASE ACTIVITY AS A BIOMARKER IN KIDNEY DISEASE - Biomarkers for diagnosis and differentiation between stages of kidney diseases. Methods of treatments and identification of novel therapies are provided. | 08-02-2012 |
| 20120195877 | DEGRADABLE COMPOSITE MATERIAL CONTAINING CHITIN OR CHITOSAN - The object of the present invention is to provide a degradable composite material that contains at least one type of polysaccharide selected from chitin and chitosan, and has self-degrading capability. By supporting an enzyme capable of hydrolyzing chitin and chitosan on a molded article containing at least one type of polysaccharide selected therefrom, the polysaccharide can be slowly degraded in an environment where moisture is present such as a living body. | 08-02-2012 |
| 20120207741 | Enzymes For Pharmaceutical Use - The pharmaceutical use of proteases related to a protease derived from | 08-16-2012 |
| 20120213762 | LYSOSOMAL TARGETING PEPTIDES AND USES THEREOF - The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor. | 08-23-2012 |
| 20120219538 | STABILIZED PROTEIN FORMULATIONS AND USE THEREOF - The present invention is directed to stable protein formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing therapeutic proteins in aqueous solution. | 08-30-2012 |
| 20120230973 | LACTASE PREPARATION - Disclosed is a lactase preparation which does not undergo the deactivation of lactase even when the preparation is ingested prior to the ingestion of a lactase-containing food or drink such as a milk product and therefore can decompose lactase stably and which can prevent the symptoms of lactase intolerance. Specifically disclosed is a lactase preparation comprising lactase and at least one component selected from trisodium citrate, potassium sodium tartrate, calcium carbonate, sodium carbonate and calcium hydrogen phosphate which acts as an antacid. The lactase preparation is characterized by being intended to be ingested prior to the ingestion of a lactase-containing food or drink to decompose lactase. In the lactase preparation, the antacid is contained at such a content per unit dosage form that the pH value in the stomach can be increased to 4 or higher after the ingestion of the preparation. | 09-13-2012 |
| 20120230974 | ALKALINE ALPHA GALACTOSIDASE FOR THE TREATMENT OF FABRY DISEASE - A method of treating Fabry is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of alkaline alpha galactosidase, thereby treating Fabry disease. | 09-13-2012 |
| 20120237494 | Compositions Containing Zinc PCA And Anogeissus Extract - A topical composition comprising at least one extract from the | 09-20-2012 |
| 20120237495 | METHOD OF TREATMENT USING SOLUBILIZED PROTEIN COMPOSITION OBTAINED FROM EGGSHELL MEMBRANE - The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention. | 09-20-2012 |
| 20120258089 | SOLUBLE BETA-N-ACETYLGLUCOSAMINIDASE BASED ANTIBIOFILM COMPOSITIONS AND USES THEREOF - The present invention provides compositions comprising an antibiofilm enzyme, a soluble β-N-acetylglucosaminidase similar to the dspB gene (DispersinB®), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular, wound care devices using soluble β-N-acetylglucosaminidase based antimicrobial compositions. | 10-11-2012 |
| 20120276078 | GLYCOSIDASE ENZYMES - A thermostable glycosidase enzymes derived from various | 11-01-2012 |
| 20120282239 | NOVEL MANNANASE VARIANTS - The present disclosure provides novel mannanase variants which have an amino acid sequence that varies from that of the parent/wild type | 11-08-2012 |
| 20120288488 | Compositions and Methods of Use for Livestock Pen Spray - Compositions and methods for preventing or controlling bacteria, viruses and parasitic growths that cause diarrhea, pneumonia and septicemia in animals comprising a biocidal system comprised of a primary biocide and a pH buffer component; a cationic or ionic surfactant having an HLB of from about 5 to about 30; a thickening agent; and an aqueous based carrier. | 11-15-2012 |
| 20120288489 | INTRANASAL DELIVERY OF THERAPEUTIC ENZYMES TO THE CENTRAL NERVOUS SYSTEM FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES - The invention provides a method to prevent, inhibit or treat one or more neurological symptoms associated with a lysosomal storage disease in a mammal in need thereof, which includes intranasally administering to the mammal a composition comprising an effective amount of a lysosomal storage enzyme or a recombinant adeno-associated virus vector comprising an open reading frame encoding a lysosomal storage enzyme. Also provided are compositions and devices useful in the methods. | 11-15-2012 |
| 20120288490 | Variants of A Lysozyme And Polynucleotides Encoding Same - The present invention relates to variant lysozymes. The present invention also relates to polynucleotides encoding the variant lysozymes and to nucleic acid constructs, vectors, and host cells comprising the polynucleotide. | 11-15-2012 |
| 20120308549 | PROCESS FOR PRODUCTION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALPHA-MANNOSIDASE - The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis. | 12-06-2012 |
| 20120315263 | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases - The invention provides a method and compositions for treating a subject with a lysosomal storage disease such as gaucher disease, by administering to a subject with a lysosomal storage disease a therapeutically effective amount of composition comprising at least one of a protease or peptidase in an amount sufficient to ameliorate, reduce or improve at least one symptom of the disease. The invention also provides dietary supplements for subjects having lysosomal storage diseases. | 12-13-2012 |
| 20130011381 | MODIFIED ENZYME TREATMENT METHOD - Disclosed is a method for the treatment of lysosomal storage disease in mammals wherein the mammal is administered a therapeutically effective amount of an isolated, modified recombinant β-glucuronidase whereby said storage diseased disease is relieved in the brain and visceral organs of the mammal. There is also disclosed an isolated, modified recombinant β-glucuronidase wherein the modification is having its carbohydrate moieties chemically modified so as to reduce its activity with respect to mannose and mannose 6-phosphate cellular delivery system while retaining enzymatic activity. Also disclosed are other lysosomal enzymes within the scope of the invention. | 01-10-2013 |
| 20130028882 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE - Novel compositions comprising carrageenans well as methods of their use are disclosed. Certain novel compositions are useful, inter alia, in the prevention, inhibition and/or treatment of dengue fever (DF), dengue fever shock syndrome (DSS) or dengue hemorrhagic fever (DHF). Other compositions are useful, inter alia, for treatment of viral infections. | 01-31-2013 |
| 20130039901 | Treatment of Pompe's Disease - The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. | 02-14-2013 |
| 20130052183 | METHODS FOR THE TREATMENT OF MORGELLONS DISEASE - Provided herein are compositions and methods of using such compositions to treat Morgellons and other symptoms associated with skin and nail diseases and disorders. | 02-28-2013 |
| 20130058912 | Therapeutic Charge Engineered Variants of Lysozyme and Methods for Using Same to Treat Infections - The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrobial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug. | 03-07-2013 |
| 20130058913 | Lactase Formulations - A particulate composition comprising a plurality of particles comprising lactase and a protective material are provided. The particles have a size that is not perceptible or is minimally perceptible on the human tongue. The particulate composition can be made by a method that comprises the steps of providing a lactase, providing a protective material, and forming a particulate composition comprising a plurality of particles comprising the lactase and the protective material in a size that is not perceptible or barely perceptible on the human tongue. The particulate composition can be used by applying the lactase composition to a food article or by using the lactase composition in the course of consuming the food article. | 03-07-2013 |
| 20130064805 | HIGHLY FUNCTIONAL ENZYME HAVING ALPHA-GALACTOSIDASE ACTIVITY - The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 03-14-2013 |
| 20130071374 | RNA Interferases and Methods of Use Thereof - The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials. | 03-21-2013 |
| 20130095092 | RECOMBINANT HUMAN NAGLU PROTEIN AND USES THEREOF - The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases. | 04-18-2013 |
| 20130129708 | SELF-RENEWAL PROMOTER FOR NEURAL STEM CELLS AND METHOD FOR USING SAME - An object of the present invention to provide an agent for promoting the self-renewal of the neural stem cells and a method of using the same. ECF-L contained in a culture supernatant of endothelial progenitor cells derived from bone marrow has an effect of promoting the self-renewal of neural stem cells. Accordingly, ECF-L can be used as an ingredient of an agent for promoting the self-renewal of the neural stem cells, a pharmaceutical composition for growing the neural stem cells, and a pharmaceutical composition for treating a disease associated with neural dysfunction. | 05-23-2013 |
| 20130129709 | Fraction of Proteins and Peptides Derived from Egg White and Protein Derived From Egg White and Use Thereof as Anti Listeria Agent - The invention relates to a fraction of peptides and/or proteins that are derived from egg white and that are capable of binding heparin, for its anti- | 05-23-2013 |
| 20130136729 | COMPOSITIONS AND METHODS FOR TARGETING AND TREATING DISEASES AND INJURIES USING ADENO-ASSOCIATED VIRUS VECTORS - The present application discloses compositions and methods useful for targeting and treating injured or diseased muscle, including cardiac and skeletal muscle. Disclosed herein are adenoviral vectors modified to contain enhancers, promoters, and genes to target muscle with high efficiency and to induce tissue specific gene expression of transgenes. | 05-30-2013 |
| 20130136730 | METHODS AND MATERIALS FOR REDUCING BIOFILMS - This document provides methods and materials related to reducing biofilms. For example, enzymes (e.g., glycosyl hydrolases), nucleic acid molecules encoding enzymes, host cells containing nucleic acid encoding enzymes, and methods for using enzymes to reduce biofilms and infections associated with biofilms are provided. | 05-30-2013 |
| 20130156750 | Compositions and Methods for Using Human YKL-40 to Treat Acute Lung Injury - The invention includes methods of treating oxidant-mediated acute lung injury in a subject by administration of a chitinase-like protein molecule, or an activator thereof. The invention also includes methods of assessing the level of a chitinase-like protein molecule in a subject as a marker of the prognosis of a subject suffering from acute lung injury. | 06-20-2013 |
| 20130164275 | METHOD FOR TREATING ACIDOSIS IN RUMINANTS - The present invention provides a method for treating acidosis in a ruminant. The method includes administering an effective amount of a naturally derived inhibitor of a carbohydrate degrading enzyme to the ruminant. Such enzymes include amylase and glucosidase. In addition, the carbohydrate degrading enzyme may be endogenous or exogenous to the ruminant. | 06-27-2013 |
| 20130164276 | AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND Rho KINASE ACTIVATION INHIBITOR - An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. | 06-27-2013 |
| 20130189241 | REGULATED DELIVERY SYSTEMS FOR INNER EAR DRUG APPLICATION AND USES THEREOF - The invention relates to a controlled release delivery compositions and methods of using them for pathologies associated with Otorhinolaryngology and Head and Neck. Specifically, the invention relates to regulating drug delivery by the use of chitosan based matrices together with chitosanases. | 07-25-2013 |
| 20130195834 | TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II - Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. | 08-01-2013 |
| 20130195835 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 08-01-2013 |
| 20130195836 | MANNOSE RECEPTOR C TYPE 1 (MRC1) CODON OPTIMIZED CELL LINE AND USES THEREOF - Described herein are isolated nucleic acid molecules comprising nucleotide sequence encoding mannose receptor, C type 1 (MRC1) wherein the 5′ region of the nucleotide sequence encoding MRC1 is codon optimized; cells comprising such nucleic acid molecules; and methods of detecting antibody production, e.g., neutralizing antibody production, in a subject being treated for Gaucher disease using such cells. | 08-01-2013 |
| 20130202582 | AGENT DELIVERY SYSTEM CAPABLE OF SELECTIVELY RELEASING AN AGENT - The present invention provides a composition for selectively delivering an active agent to a portion of an organism. The composition comprises first and second polymer portions, having first and second functional groups attached as a side-chain thereto, respectively. The first and second functional groups form cross-links between the first and second polymer portions. The cross-links are capable of being broken by a substance of the organism, thereby resulting in release of the active agent. The composition provides a novel means for controlling the selective release of the active agent in the organism. | 08-08-2013 |
| 20130224177 | METHOD OF REGULATING FERTILIZING ABILITY USING CYCLIC ADP-RIBOSE AND CD38 - The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD38 and to a method of promoting fertilization by promoting the synthesis of cyclic ADP-ribose to increase sperm motility. Also, the present invention relates to a pharmaceutical composition for contraception and a method for inhibiting fertilization, which can inhibit the expression or function of cyclic ADP-ribose to reduce sperm motility, thereby inhibiting fertilization. | 08-29-2013 |
| 20130236443 | SURFACE PROTECTION OF EXPOSED BIOLOGICAL TISSUES - The invention relates to a biodegradable barrier network comprising at least two macromolecular substances, one being anionic and the other one cationic. The invention also relates to applicators and kits comprising components to be used to create said biodegradable barrier network. The invention also relates to the use of said applicator or kit in therapy, such as in medicine, veterinary medicine and horticulture. | 09-12-2013 |
| 20130243746 | METHODS AND MATERIALS FOR TREATMENT OF POMPE'S DISEASE - This document relates to molecular complexes having acid alpha glucosidase activity and at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell. | 09-19-2013 |
| 20130259852 | LYSOZYME GEL FORMULATIONS - The present invention relates to formulations of gelled lysozyme achieved by the addition of water to a lysozyme suspension in a solvent, such as an alcohol, with retention of enzymatic activity. It was surprisingly discovered that lysozyme itself is a gelling substance (self-gel) and, therefore, it can be advantageously formulated into topical compositions without the addition of other gelling substances such as cellulose, starch or other polysaccharides. The activity of the lysozyme is enhanced as compared to other formulations of comprising lysozyme. The formulations contained in the present invention are useful in methods in the fields of therapeutics, disinfectants, sanitizers, personal hygiene, and cosmetics for human and veterinary use. | 10-03-2013 |
| 20130266554 | Lysozymes - The present invention is directed to lysozyme variants and nucleotide sequences encoding same. The lysozyme variants have antimicrobial and/or lysozyme activity and comprise an alteration of an amino acid sequence at one or more positions. The present invention is also directed to methods for producing and of using the | 10-10-2013 |
| 20130266555 | THERAPEUTIC AGENT FOR DISC HERNIATION - The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk. | 10-10-2013 |
| 20130273026 | COMPOSITION AND METHOD FOR MODULATING INFLAMMATORY MOLECULES WITH AMYLASE - A method and composition for treating in a mammalian subject a condition accompanied or caused by IgE mediated histamine release from mast cells comprising administering to a subject in need of such treatment a therapeutically effective amount of the pharmaceutical composition an amylase peptide or derivative thereof. | 10-17-2013 |
| 20130295077 | TREATMENT OF SANFILIPPO SYNDROME TYPE B - Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety. | 11-07-2013 |
| 20130302309 | Non-animal soft capsule shell composition having improved disintegration and shell hardness - The present invention relates to a non-animal soft capsule shell composition having improved disintegration stability and shell hardness. More particularly, the present invention relates to a non-animal soft capsule shell composition and to a method for preparing same, in which an antioxidant and a disintegration aid are added to the non-animal soft capsule shell composition that is typically made of starch or a starch derivative, gums, a plasticizer, a buffering agent, and purified water which inhibit starch retrogradation and thus inhibit an increase in disintegration stability and capsule shell hardness, thereby improving disintegration stability and shell hardness. | 11-14-2013 |
| 20130309220 | COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS - Certain embodiments are directed to methods of treating a condition associated with microbial infection in a subject having such a condition comprising administering to the subject a composition comprising an effective amount of (a) lysozyme and (b) N-acetyl glucosamine polymer. | 11-21-2013 |
| 20130323224 | USE OF MYCOBACTERIUM SMEGMATIS TREHALOSE DIMYCOLATE HYDROLASE - Methods are disclosed herein for treating an infection with a | 12-05-2013 |
| 20130323225 | Broccoli Based Nutritional Supplements - A nutritional supplement is provided containing two broccoli based components that are combined and, when ingested, react in the intestines to provide sulforaphane. Processes for producing the broccoli components of the nutritional supplement are also provided. The broccoli components are treated separately using supercritical fluid extraction to remove oils. The temperature and pressure of the supercritical extraction processes are controlled to provide broccoli components having the desired properties for the nutritional supplement. | 12-05-2013 |
| 20130323226 | Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer - A method of altering the targeting and/or cellular uptake efficiency of an adeno-associated virus (AAV) viral vector having a capsid containing an AAV9 cell surface binding domain is described. The method involves modifying a clade F cell surface receptor which comprises a glycan having a terminal sialic acid residue and a penultimate β-galactose residue. The modification may involve retargeting the vector by temporarily functionally ablate AAV9 binding in a subset of cells, thereby redirecting the vector to another subset of cells. Alternatively, the modification may involve increasing cellular update efficiency by treating the cells with a neuraminidase to expose cell surface β-galactose. Also provided are compositions containing the AAV9 vector and a neuraminidase. Also provided is a method for purifying AAV9 using β-galactose linked to solid support. Also provided are mutant vectors which have been modified to alter their targeting specificity, including mutant AAV9 in which the galactose binding domain is mutated and AAV in which an AAV9 galactose binding domain is engineered. | 12-05-2013 |
| 20130336954 | Staphylococcal Phage2638A Endolysin Amidase Domain Is Lytic for Staphylococcus aureus - is notorious for developing resistance to virtually all antibiotics to which it is exposed. Staphylococcal phage 2638A endolysin is a peptidoglycan hydrolase that is lytic for | 12-19-2013 |
| 20130336955 | ANTIMICROBIAL FUSION COMPOUNDS AND USES THEREOF - A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C. | 12-19-2013 |
| 20130344054 | VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY - Described herein are variant, recombinant β-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type β-glucocerebrosidase. Also provided herein are variant, recombinant β-glucocerebrosidase proteins characterized as retaining more catalytic activity relative to recombinant wild-type β-glucocerebrosidase. Further described herein are variant, recombinant β-glucocerebrosidase proteins that can have amino acid variations at one or more of the following positions: 316, 317, 321 and 145. Methods of making the variant, recombinant β-glucocerebrosidase proteins are also described as well as methods of treating patients having lysosomal storage diseases. | 12-26-2013 |
| 20140017224 | NOVEL ENDOLYSIN - The present invention relates to a polypeptide with endolysin activity comprising an amino acid sequence according to SEQ ID No. 1 and fragments or derivatives thereof, or fusion proteins derived thereof. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide, fragment, derivative or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide, fragment, derivative or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide, fragment, derivative or fusion protein. | 01-16-2014 |
| 20140023633 | USE OF BETA-1,3 (4)-ENDOGLUCANOHYDROLASE, BETA-1,3 (4)-GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTION - A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species. | 01-23-2014 |
| 20140037611 | Treatment of Pompe's Disease - The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. | 02-06-2014 |
| 20140037612 | SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A - The invention relates, in part, to improved methods of administering α-galactosidase A for the treatment of α-galactosidase A deficiencies including Fabry disease. | 02-06-2014 |
| 20140044699 | PROTEINS HAVING ACQUIRED A-GALACTOSIDASE ACTIVITY - The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an α-galactosidase activity through alteration of the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 02-13-2014 |
| 20140050714 | USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY - The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP. | 02-20-2014 |
| 20140050715 | PROTEIN HYDROLYSATES AS AGENTS FOR OVERCOMING ADDICTION - This invention is directed to the use of a protein hydrolysate, and in particular an egg lysozyme hydrolysate to assist an animal, including a human in overcoming an addition, or by breaking an unwanted habit. | 02-20-2014 |
| 20140065127 | Staphylococcus haemolyticus Prophage PhiSH2 Endolysin is Lytic for Staphylococcus aureus - Methicillin-resistant (MRSA) and multi-drug resistant strains of | 03-06-2014 |
| 20140065128 | TREATMENT FOR IgE-MEDIATED DISEASE - The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies. | 03-06-2014 |
| 20140072549 | STREPTOCOCCUS BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIA - The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including | 03-13-2014 |
| 20140079683 | Multifunctional Cellulase And Hemicellulase - A multifunctional polypeptide capable of hydrolyzing cellulosic materials, xylan, and mannan is disclosed. The polypeptide includes the catalytic core (cc) of | 03-20-2014 |
| 20140086896 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders - The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease. | 03-27-2014 |
| 20140099296 | TOPICALLY OR ORALLY APPLIED ALOE, DISTILLED WATER, SODIUM CHLORIDE, AND LYSOZYME MIXTURE AND METHOD OF PRODUCING THE MIXTURE - A skin and/or oral treatment mixture for treating tattooed or pierced skin such as that resulting from a body piercing, oral piercing, or tattoo procedure includes non-iodized sodium chloride, distilled water, | 04-10-2014 |
| 20140112907 | USE OF BETA-1,3 (4)-ENDOGLUCANOHYDROLASE, BETA-1,3 (4)-GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTION - A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species. | 04-24-2014 |
| 20140134149 | ENZYMES FOR INHIBITING GROWTH OF BIOFILMS AND DEGRADING SAME - Enzymes for inhibiting growth of biofilms and degrading biofilms. The enzymes comprise glycosyl hydrolases capable of degrading biofilms. The enzymes are formulated in compositions with and without antimicrobial agents. The enzymes with and without the antimicrobial agents are delivered to biofilms to degrade the biofilms and treat infections of microorganisms associated with the biofilms, delivered to surfaces to inhibit growth of biofilms thereon, and administered to animals to inhibit growth of biofilms therein. | 05-15-2014 |
| 20140134150 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES - Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions. | 05-15-2014 |
| 20140161788 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 06-12-2014 |
| 20140170131 | Compositions and Methods for the Treatment and Prevention of Infections Caused by Staphylococcus aureus Bacteria - The present invention relates to antimicrobial deoxyribonuclease-based compositions that inhibit growth and proliferation of | 06-19-2014 |
| 20140186326 | MODIFIED ACID ALPHA GLUCOSIDASE WITH ACCELERATED PROCESSING - A modified human acid alpha-glucosidase polypeptide is provided, as well as methods of making and using modified human acid alpha-glucosidase to treat glycogen storage disorders. | 07-03-2014 |
| 20140193390 | High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease - The present application provides for compositions comprising high concentrations of acid α-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation. | 07-10-2014 |
| 20140193391 | Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces - A composition for treating keratin surfaces to stimulate selective catabolysis and improve cellular viability comprising at least one autophagy activator and at least one DNA repair enzyme, and a method for improving selective catabolysis and cellular viability by treating with the composition. | 07-10-2014 |
| 20140193392 | METHODS AND COMPOSITIONS TO DETECT THE LEVEL OF LYSOSOMAL EXOCYTOSIS ACTIVITY AND METHODS OF USE - Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile. As such, the level of lysosomal exocytosis activity and/or lysosomal sialidase activity is predictive of a diagnosis and/or prognosis of cancer, chemotherapy resistance or dementia associated with Alzheimer's disease. | 07-10-2014 |
| 20140219986 | DOSING REGIMENS FOR THE TREATMENT OF FABRY DISEASE - The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the treatment of Fabry disease. | 08-07-2014 |
| 20140219987 | STABILIZED COMPOSITIONS OF PROTEINS HAVING A FREE THIOL MOIETY - Compositions of proteins having free thiols, and methods of making and using such compositions, are described. | 08-07-2014 |
| 20140219988 | RRECOMBINANT HUMAN SAPOSIN B PROTEIN CONTAINING PHOSPHORYLATED GLUCOSE RING AND USE THEREOF - The present invention provides a means to ensure a further increase in the therapeutic effects provided by enzyme replacement therapy against lysosomal disease. The present invention is directed to a recombinant human saposin B protein containing phosphorylated carbohydrate chains, a lysosomal enzyme activator comprising such a recombinant protein, and a pharmaceutical composition for treatment of lysosomal disease, which comprises such a recombinant protein and a lysosomal enzyme, etc. | 08-07-2014 |
| 20140234289 | EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY - Engineered nucleases (e.g., zinc finger nucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and others) are promising tools for genome manipulation and determining off-target cleavage sites of these enzymes is of great interest. We developed an in vitro selection method that interrogates 10 | 08-21-2014 |
| 20140242061 | COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE - Methods and compositions for treating Gaucher disease are described. | 08-28-2014 |
| 20140255381 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | 09-11-2014 |
| 20140255382 | SOLID COMPOSITION CONTAINING A HYPOTHIOCYANITE SALT - The present invention relates to a solid composition including at least one hypothiocyanite (OSCN | 09-11-2014 |
| 20140255383 | RECOMBINANT HUMAN NAGLU PROTEIN AND USES THEREOF - The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases. | 09-11-2014 |
| 20140308264 | VEGF Analogs and Methods of Use - Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders. | 10-16-2014 |
| 20140308265 | ANTI-MICROBIAL COMPOSITIONS AND RELATED METHODS - The claimed invention is directed to compositions and methods effective in preventing microbial contamination or reducing microbial count associated with a contaminated surface, comprising a biocidal system comprised of a primary biocide, a pH buffer agent, a surfactant, all in an aqueous based carrier, wherein the compositions may be considered environmentally friendly. | 10-16-2014 |
| 20140328824 | Diagnostic and Therapeutic Methods and Their Application in Amyotrophic Lateral Sclerosis (ALS) - The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject. | 11-06-2014 |
| 20140328825 | MAKING AND USING IN VITRO-SYNTHESIZED ssRNA FOR INTRODUCING INTO MAMMALIAN CELLS TO INDUCE A BIOLOGICAL OR BIOCHEMICAL EFFECT - The present invention relates to compositions, kits and methods for making and using RNA compositions comprising in vitro-synthesized ssRNA inducing a biological or biochemical effect in a mammalian cell or organism into which the RNA composition is repeatedly or continuously introduced. In certain embodiments, the invention provides compositions and methods for changing the state of differentiation or phenotype of a human or other vertebrate cell. For example, the present invention provides mRNA and methods for reprogramming cells that exhibit a first differentiated state or phenotype to cells that exhibit a second differentiated state or phenotype, such as to reprogram human somatic cells to pluripotent stem cells. | 11-06-2014 |
| 20140348815 | SPRAY DRY METHOD FOR ENCAPSULATION OF BIOLOGICAL MOIETIES AND CHEMICALS IN POLYMERS CROSS-LINKED BY MULTIVALENT IONS FOR CONTROLLED RELEASE APPLICATIONS - Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution. | 11-27-2014 |
| 20140348816 | USE OF COMPLEX FORMS OF CALMODULIN-LIKE SKIN PROTEIN CLSP - The invention also relates to the use of these complex forms for the purposes of screening for biological or chemical compounds capable of modulating a biological activity of said complex forms and/or for preparing and/or improving a pluristratified cell model. | 11-27-2014 |
| 20140363418 | METHOD OF PRODUCING COLLAGEN FROM HYDROLYZED EGG MEMBRANE - A method of producing collagen from hydrolyzed egg membrane includes combining 95% alcohol, cold water, a bacterial neutralase and/or alcalase, 14L, sodium bisulfite, and egg membrane. Once combined the solution is mixed slowly and then heated to a desired pH range. Once a desired temperature is reached, the heated solution is set aside to digest for a prolonged period of time. Next, the digested solution is centrifuged and filtered. Finally, the filtered solution is spray dried and packaged. | 12-11-2014 |
| 20140377245 | METHODS AND COMPOSITIONS TO DETECT THE LEVEL OF LYSOSOMAL EXOCYTOSIS ACTIVITY AND METHODS OF USE - Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile. As such, the level of lysosomal exocytosis activity and/or lysosomal sialidase activity is predictive of a diagnosis and/or prognosis of cancer, chemotherapy resistance or dementia associated with Alzheimer's disease. | 12-25-2014 |
| 20140377246 | ENZYME REPLACEMENT THERAPY FOR TREATING MPS VII RELATED BONE LESIONS USING A CHEMICALLY MODIFIED ENZYME - The invention relates to a method of treating mucopolysaccharidoses using enzyme replacement therapy with chemically modified lysosomal enzymes. More specifically the method relates to administering chemically modified lysosomal enzymes intraperitoneal injection. In addition, the invention relates to treating type VII mucopolysaccharidoses or mucopolysaccharidoses type VII related bone lesions with a chemical modified β-glucuronidase, wherein the modified β-glucuronidase may be administered 5 weeks after birth, and or may be administered intraperitoneally. | 12-25-2014 |
| 20150010526 | EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY - Engineered nucleases (e.g., zinc finger nucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and others) are promising tools for genome manipulation and determining off-target cleavage sites of these enzymes is of great interest. We developed an in vitro selection method that interrogates 10 | 01-08-2015 |
| 20150010527 | DNASE I POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, METHODS OF PRODUCING DNASE I AND USES THEREOF IN THERAPY - Plant-expressed human recombinant DNase proteins, nucleic acid constructs for expression of the human recombinant DNase I in plant cells, cells expressing the nucleic acid construct and therapeutic uses thereof are disclosed. Particularly, compositions and methods for treating pulmonary and/or respiratory conditions by inhalation of the plant-expressed human recombinant DNase I are provided. | 01-08-2015 |
| 20150017149 | PHARMACEUTICAL OR NUTRITIONAL COMPOSITIONS CONTAINING GALACTOSIDASE, AND THEIR USE - The present disclosure relates to pharmaceutical or nutritional compositions containing α-galactosidase and β-galactosidase and their use in the prevention and/or treatment of gastroesophageal reflux disease; in particular the present disclosure related to pharmaceutical or nutritional compositions. | 01-15-2015 |
| 20150017150 | Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract - The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition. | 01-15-2015 |
| 20150023945 | Lysozymes - The present invention is directed to lysozyme variants and nucleotide sequences encoding same. The lysozyme variants have antimicrobial and/or lysozyme activity and comprise an alteration of an amino acid sequence at one or more positions. The present invention is also directed to methods for producing and of using the | 01-22-2015 |
| 20150037313 | MIXTURE OF PEPTIDE-BOUND TRYPTOPHAN AND POLYPEPTIDE-BOUND TRYPTOPHAN - The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan. | 02-05-2015 |
| 20150044193 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION - Compositions and methods are provided for treating a disorder characterized by α-synuclein dysfunction and/or altered lipid metabolism. | 02-12-2015 |
| 20150044194 | High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease - The present application provides for compositions comprising high concentrations of acid α-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation. | 02-12-2015 |
| 20150050263 | Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System - Described are novel salts of the compound (3R,4R,5S)-5-(difluoromethyl) piperidine-3,4-diol, as well as methods of using the same for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease and/or Parkinson's disease. | 02-19-2015 |
| 20150071907 | COMPOSITIONS AND METHODS FOR TREATING TYPE III GAUCHER DISEASE - Methods and compositions for treating Gaucher disease are described. | 03-12-2015 |
| 20150079065 | KLOTHO VARIANT POLYPEPTIDES AND USES THEREOF IN THERAPY - Disclosed are Klotho variant proteins in which residue Glu414 and/or residue Asp238 is substituted with an amino acid different than L-Glu or L-Asp, respectively, as well as polynucleotides encoding the variant proteins, and the use thereof in therapy, especially for the treatment of cancers, especially breast cancer and pancreatic cancer. | 03-19-2015 |
| 20150079066 | MEANS AND METHODS FOR GENERATING IMPROVED PROTEINS - The disclosure provides a general method for the production of protein variants with a reduced aggregation propensity without affecting the thermodynamic stability of the variant with respect to the wild-type protein. | 03-19-2015 |
| 20150086529 | Therapeutic Burn Gel - Therapeutic Radiation Burn Gel is an invention that promotes the healing of radiated skin. It works by softening the layers of necrotic tissue which form (in the skin) post radiation. The softening of the necrotic tissue allows for it to be safely and gently peeled away, in order to promote healing. In addition, the Gel is comprised of natural ingredients: Amylase contained in an Aloe Vera gel base. Amylase is an enzyme which is a component of normal human saliva. It softens radiated tissue by way of its lysing action on the sugars and starches which occur naturally in human skin. | 03-26-2015 |
| 20150086530 | DOSING REGIMENS FOR THE TREATMENT OF POMPE DISEASE - The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxynojirimycin and enzyme replacement therapy for the treatment of Pompe disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of 1-deoxynojirimycin hydrochloride and alglucosidase alfa for the treatment of Pompe disease. | 03-26-2015 |
| 20150093371 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE - Novel compositions comprising carrageenans well as methods of their use are disclosed. Certain novel compositions are useful, inter alia, in the prevention, inhibition and/or treatment of dengue fever (DF), dengue fever shock syndrome (DSS) or dengue hemorrhagic fever (DHF). Other compositions are useful, inter alia, for treatment of viral infections. | 04-02-2015 |
| 20150110771 | ENZYMES AND METHODS FOR CLEAVING N-GLYCANS FROM GLYCOPROTEINS - Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity. | 04-23-2015 |
| 20150110772 | CUCURBITURIL-BASED HYDROGELS - The invention provides hydrogel, wherein the hydrogel has a supramolecular cross-linked network obtainable or obtained from the complexation of an aqueous composition including a host, such as cucurbituril, and one or more polymers having suitable guest functionality. One or more polymers in the aqueous composition may have a molecular weight of 50 kDa or more, such as 200 kDa or more. The hydrogel may hold a component, such as a therapeutic compound or a biological molecule. The hydrogels are suitable for use in medicine. | 04-23-2015 |
| 20150118217 | TREATMENT OF DISEASE CONDITIONS VIA ADMINISTRATION OF DNA REPAIR ENZYME - The present invention is directed to compositions and methods of preserving viability of islets of Langerhans for transplantation, and treating various disease and other abnormal or pathological conditions, including inflammatory bowel disease, ischemic heart disease, acute lung injury, acute respiratory distress syndrome and radiation-induced brain injury, with DNA repair enzymes that are directed to the mitochondria. | 04-30-2015 |
| 20150139976 | NOVEL INSECTICIDAL CHITINASE PROTEIN ITS ENCODING NUCLEOTIDE AND APPLICATION THEREOF - A novel insecticidal chitinase protein from fern | 05-21-2015 |
| 20150139977 | XYLANASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal β-1,4-xylosidic linkages or endo-β-1,4-glucanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature. | 05-21-2015 |
| 20150147309 | ALLOSTERIC CHAPERONES AND USES THEREOF - The present invention relates to an allosteric non-inhibitory chaperone of the lysosomal acid alpha-glucosidase (GAA) for use in the treatment of a pathological condition characterized by a deficiency of the lysosomal acid alpha-glucosidase (GAA), to pharmaceutical composition thereof, to a method for increasing the activity of GAA in a subject and to a method for identifying an allosteric non-inhibitory chaperone for GAA. | 05-28-2015 |
| 20150147310 | TARGETED ENZYME COMPOUNDS AND USES THEREOF - The present invention is related to a compound that includes (a) α-L-iduronidase (IDUA), fragment, or analog thereof and (b) a targeting moiety, for example, where compound is a fusion protein including IDUA and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating mucopolysaccharidosis type I (MPS-I) using such compounds. | 05-28-2015 |
| 20150147311 | HIGH FORCE AND HIGH STRESS DESTRUCTURING OF CELLULOSIC BIOMASS - A process for mechanical destructuring of cellulosic biomass was developed that makes use of a short application of high compression, impact, and shearing forces. The biomass may be destructured using a specific energy input that is less than 40% of the total combustible energy of the biomass. The destructured biomass, with or without saccharification and/or in-feed glycosyl hydrolase enzymes, may be used in feed applications. | 05-28-2015 |
| 20150290134 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES - Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions. | 10-15-2015 |
| 20150290299 | BACTERIOPHAGE LYSIN AND ANTIBIOTIC COMBINATIONS AGAINST GRAM POSITIVE BACTERIA - The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly | 10-15-2015 |
| 20150306185 | HEPARANASE AND ITS USES RELATED TO EXOSTOSES - Methods of treating or preventing exostosis in a subject comprising administering to a subject with exostosis or at risk of developing exostosis an effective amount of an agent that that cleaves heparan sulfate or an agent that increases expression of an enzyme that cleaves heparan sulfate are provided herein. | 10-29-2015 |
| 20150306186 | PROCESS FOR PRODUCTION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALPHA-MANNOSIDASE - The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis. | 10-29-2015 |
| 20150306187 | SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A - The invention relates, in part, to improved methods of administering α-galactosidase A for the treatment of α-galactosidase A deficiencies including Fabry disease. | 10-29-2015 |
| 20150313830 | Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces - A method for increasing cellular viability in cells of keratin surfaces after exposure to UV light and/or detoxifying cells of debris that impedes healthy metabolic function by topically applying to the keratin surface a composition containing at least one autophagy activator and at least one DNA repair enzyme and a method for making a topical composition comprising the steps of (a) identifying an ingredient that activates cellular autophagy in keratinocyte cultures in vitro, and (b) formulating the ingredient into a topical composition in combination with at least one DNA repair enzyme. | 11-05-2015 |
| 20150313970 | INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES - Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage diseases which affect both brain and visceral organs. | 11-05-2015 |
| 20150343032 | ULTRAPURE HYPOALLERGENIC SOLUTIONS OF SACROSIDASE - One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day. | 12-03-2015 |
| 20150344859 | COMPOSITION FOR USE IN MYCOBACTERIA THERAPY - The present invention relates to a composition having the activity of degrading the cell wall of a | 12-03-2015 |
| 20150366951 | SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF - The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders. | 12-24-2015 |
| 20150368628 | DEIMMUNIZED GELONIN MOLECULES AND THERAPIES - Recombinant gelonin polypeptides with decreased antigenicity are provided. Cell-targeted constructs comprising said recombinant gelonin polypeptides are also provided. Such constructs can be used in methods for targeted cell killing, such as for treatment of cell proliferative diseases (e.g., cancer). | 12-24-2015 |
| 20150374740 | COMPOSITION AND METHOD FOR PROMOTING REDUCTION OF HEAT STRESS IN ANIMALS - Disclosed herein is a method for promoting reduction of heat stress in animals, as well as a composition for use in the disclosed method. The composition comprises a glucan, silica, mineral clay, mannan, and optionally an endoglucanohydrolase, and may be administered to an animal that is susceptible to or suffers from heat stress. | 12-31-2015 |
| 20150374802 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES - The invention provides compositions and methods for treating inflammatory diseases, such as cardiac or hepatic inflammatory diseases, involving the use of parasite-derived neurotrophic factor (PDNF), or fragment of PDNF. The invention also provides compositions featuring PDNF, or a fragment thereof, and methods for using such compositions for the proliferation and/or mobilization of a stem cell (e.g., cardiac stem cell) or progenitor cell (e.g., hepatic progenitor cell). In one aspect, the invention provides a method of decreasing inflammation in a nonneuronal tissue of a subject. In another aspect, the invention provides a method of decreasing inflammation in a cardiac, liver, pancreas, or gastrointestinal tissue of a subject. In still another aspect, the invention provides a method of increasing expression of an anti-inflammatory factor in a non-neuronal cell or tissue | 12-31-2015 |
| 20160010071 | ENDOLYSIN OBPGPLYS | 01-14-2016 |
| 20160022823 | Albumin conjugated temperature and pH-sensitive multi-block copolymer, a method of preparation thereof and drug delivery system using the same - The present invention relates to a conjugate of albumin and a temperature- and pH-sensitive multi-block copolymer, a method of preparation thereof, and a sustained-release drug carrier comprising the same, and more specifically, to a conjugate in which polyethylene glycol-poly(amino urethane) (PEG-PAU) or polyethylene glycol-poly(amino ester urethane) (PEG-PAEU) multi-block copolymer is conjugated to albumin, a method of preparing the same, and a long-term sustained-release drug carrier comprising the same, capable of reducing an initial burst release of drugs and improving an affinity to drugs. | 01-28-2016 |
| 20160030375 | GLYCOGEN OR POLYSACCHARIDE STORAGE DISEASE TREATMENT METHOD - A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases. | 02-04-2016 |
| 20160030528 | ANTIMICROBIAL MURAMIDASE - glycosyl hydrolase 25 (GH25) muramidase is shown here to exhibit antibacterial activity against several distinct bacterial families. Formulations and methods of use for this GH25 are provided. | 02-04-2016 |
| 20160031963 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 02-04-2016 |
| 20160031964 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 02-04-2016 |
| 20160031965 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 02-04-2016 |
| 20160038572 | Endolysins Active Against Staphylococcus Bacteria, Pharmaceutical Compositions, and Methods Relating Thereto - The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including isolated endolysin polypeptides from bacteriophage GRCS. | 02-11-2016 |
| 20160039900 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 02-11-2016 |
| 20160051528 | Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives - The present invention provides a method for increasing the activity of a mutant or wild-type α-glucosidase enzyme in vitro and in vivo by contacting the enzyme with a specific pharmacological chaperone which is a derivative of 1-deoxynojirimycin. The invention also provides a method for the treatment of Pompe disease by administration of chaperone small molecule compound which is a derivative of 1-deoxynojirimycin. The I-deoxynojirimycin derivative is substituted at the N or C1 position. Combination therapy with replacement α-glucosidase gene or enzyme is also provided. | 02-25-2016 |
| 20160051639 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF - The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies. | 02-25-2016 |
| 20160058698 | COMPOSITION FOR CONTROLLED DELIVERY OF BIOACTIVE AGENTS - The present invention relates to an injectable composition for controlled delivery of a bioactive agent. The injectable composition is capable of spontaneous gelation in situ upon administration to a subject to form a gel from which an effective amount of the bioactive agent can be released over a period of 7 days or more. | 03-03-2016 |
| 20160060655 | COMPOSITIONS AND METHODS TO TREAT LATENT VIRAL INFECTIONS - Viral infection is a persistent cause of human disease. Guided nuclease systems target the genomes of viral infections, rendering the viruses incapacitated. | 03-03-2016 |
| 20160068829 | ANTIMICROBIAL FUSION COMPOUNDS AND USES THEREOF - A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C. | 03-10-2016 |
| 20160082090 | Use of Polysaccharides for Promotion of Enzymatic Activity - This disclosure provides methods and compositions for the promotion of enzymatic activity of Target Enzymes, including but not limited to oligosaccharide/polysaccharide enzymes, protein enzymes, polynucleotide enzymes. The methods involve use of a non-naturally occurring polysaccharide (including but not limited HES) for promoting the enzymatic activity of an enzyme in liquid milieu, wherein the concentration of the polysaccharide in the composition comprising the Target Enzyme is from about 0.01% to about 55% w/v. | 03-24-2016 |
| 20160101161 | ANTI-VIRAL THERAPEUTIC FOR INFECTION OF THE EYE - The present disclosure provides novel compositions and methods for treating an infection of the eye resulting from an infection of a member of the Picornavirdae virus family. In particular, the present disclosure provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen, such as a virus. The present disclosure also comprises therapeutic compositions having sialidase activity, including protein based compounds having sialidase catalytic domains. Compounds of the disclosure can be used for treating pathogenic infection to the eye. | 04-14-2016 |
| 20160106817 | TREATMENT FOR BK POLYOMAVIRUS INFECTION - The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen. | 04-21-2016 |
| 20160120898 | METHODS AND COMPOSITIONS FOR THE DISRUPTION OF BIOFILMS AND TREATMENT OF DISORDERS CHARACTERIZED BY THE PRESENCE OF BIOFILMS - Methods and compositions are provided for the disruption of biofilms and the treatment of disorders characterized by the presence of biofilms and/or abnormally viscous and/or cohesive bodily secretions, such as mucus and sputum. Disorders that can be effectively treated using the disclosed compositions and methods include cystic fibrosis (CF), endocarditis, urinary tract infections, middle-ear infections, chronic sinusitis, gingivitis, periodontal disease, bronchiectasis, chronic obstructive pulmonary disease (COPD), asthma, bronchitis, neonatal meconium aspiration syndrome, smokers' cough, chronic tonsillitis, chronic vaginitis, and fungal or bacterial infections. The compositions, which contain an effective amount of trisodium citrate and ammonium chloride, may be administered alone or in combination with one or more known therapeutic agents. | 05-05-2016 |
| 20160122733 | METHOD OF TREATING GLYCOGEN STORAGE DISEASE - The disclosure relates, in general, to Glycogen Storage Disease and, in particular, to a method of treating Glycogen Storage Disease and to compounds and compositions suitable for use in such a method. | 05-05-2016 |
| 20160129092 | USE OF BETA-1,3 (4)-ENDOGLUCANOHYDROLASE, BETA-1,3 (4)-GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTION - A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species. | 05-12-2016 |
| 20160137994 | NOVEL HIGH FUNCTIONAL ENZYME HAVING MODIFIED SUBSTRATE SPECIFICITY OF HUMAN -HEXOSAMINIDASE B AND EXHIBITING PROTEASE RESISTANCE - Provided is a modified β-subunit of human β-hexosaminidase which has the activity derived from the α-subunit of wild-type human β-hexosaminidase and has the resistance to protease. A protein comprising an amino acid sequence having substitutions of the 312th to the 318th amino acids with glycine, serine, glutamic acid, proline, serine, glycine and threonine in order, respectively, in an amino acid sequence of a β-subunit of wild-type human β-hexosaminidase. | 05-19-2016 |
| 20160145591 | BACTERIAL LYSINS AND USES THEREOF - The present invention relates to substances and compositions thereof useful in the prevention and/or treatment of bacterial infections and disorders, in particular bacteremia caused by group B | 05-26-2016 |
| 20160151463 | COMBINATION TREATMENT FOR ATOPIC DERMATITIS | 06-02-2016 |
| 20160184408 | Variant, Recombinant Beta-Glucocerebrosidase Proteins With Increased Stability And Increased Retained Catalytic Activity - Described herein are variant, recombinant (β-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type (β-glucocerebrosidase. Also provided herein are variant, recombinant (β-glucocerebrosidase proteins characterized as retaining more catalytic activity relative to recombinant wild-type (β-glucocerebrosidase. Further described herein are variant, recombinant (β-glucocerebrosidase proteins that can have amino acid variations at one or more of the following positions: 316, 317, 321 and 145. Methods of making the variant, recombinant β-glucocerebrosidase proteins are also described as well as methods of treating patients having lysosomal storage diseases. | 06-30-2016 |
| 20160184409 | TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY - The invention provides methods of treating α-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human α-galactosidase A are also included. | 06-30-2016 |
| 20160198718 | BORON-SILANE POLYETHER COMPLEX | 07-14-2016 |
| 20160199495 | Polymer Compositions in Biomedical Applications | 07-14-2016 |
| 20170233706 | CHIMERIC ANTIBACTERIAL POLYPEPTIDES | 08-17-2017 |
| 20180020678 | METHODS, COMPOSITIONS, AND MOLECULAR TARGETS THAT EXPLOIT SYNERGIES AND SYMBIOSES IN THE TERMITE GUT | 01-25-2018 |
| 20180021366 | COMPOSITION AND METHOD FOR PROMOTING REDUCTION OF HEAT STRESS IN ANIMALS | 01-25-2018 |
| 20180021415 | A METHOD FOR IMPROVING FEED DIGESTIBILITY IN BOVINE ANIMALS | 01-25-2018 |
